Exhibit 99.1

                                    NMT Medical, Inc.
                                    27 Wormwood Street
                                    Boston, MA 02210-1625
                                    (Nasdaq/NMS:NMTI)


AT THE COMPANY             AT THE FINANCIAL RELATIONS BOARD
-------------------------  --------------------------------
John E. Ahern              General Info:    Stuart Levine, Ph.D.
Chief Executive Officer    Analyst Info:    Brian Gill
(617) 737-0930             Media Info:      Deanne Eagle
                           (212) 661-8030

FOR IMMEDIATE RELEASE
---------------------
February 2, 2001


  NMT MEDICAL ANNOUNCES RECEIPT OF NASDAQ LETTER REGARDING POTENTIAL DELISTING
  ----------------------------------------------------------------------------

BOSTON, MA, FEBRUARY 2, 2001 - NMT Medical, Inc. (Nasdaq/NMS:NMTI) announced
today pursuant to Marketplace Rule 4815(b) that it received notice on January
26, 2001 from the Nasdaq National Market (the "NNM") that the NNM had determined
to delist the Company's common stock from the NNM, effective at the opening of
business on February 5, 2001, unless the Company requests a hearing prior to
that time.  Based on the Company's review of its unaudited year-end results, the
Company requested a hearing to appeal Nasdaq's decision.  A hearing request will
stay the delisting of the Company's securities pending a decision by the Nasdaq
Listing Qualifications Panel (the "Panel").

In its notice to the Company, Nasdaq informed the Company that, based on the
Company's reported results of operations for the quarter ended September 30,
2000, the Company was no longer in compliance with the minimum $4,000,000 net
tangible assets requirement for the NNM under Marketplace Rule 4450(a)(3).
Until the Panel reaches its decision, the Company's common stock will remain
listed on the NNM.

There can be no assurance as to when the Panel will reach a decision, or that
such a decision will be favorable to the Company.  An unfavorable decision will
result in the immediate delisting of the Company's common stock irrespective of
the Company's ability to appeal the decision.

NMT Medical designs, develops and markets innovative medical devices that
utilize advanced technologies and are delivered by minimally invasive
procedures.  The Company's products are designed to offer alternative approaches
to existing complex treatments, thereby reducing patient trauma, shortening


procedure, hospitalization and recovery times, and lowering overall treatment
costs.  The Company's medical devices include self-expanding stents, vena cava
filters and septal repair devices.  The NMT Neurosciences division serves the
needs of neurosurgeons with a range of implantable and disposable products,
including cerebral spinal fluid shunts, external drainage products, and the
Spetzler(TM) Titanium Aneurysm Clip.

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including any statements
relating to results of the hearing by the Panel.  Factors that might cause such
a difference include, but are not limited to, those discussed under the heading
"Certain Factors That May Affect Future Results" included in the Management's
Discussion and Analysis of Financial Condition and Results of Operations in the
Company's Annual Report on Form 10-K for the year ended December 31, 1999, as
amended, and subsequent filings with the Securities and Exchange Commission.



                                     # # #


  To receive NMT Medical's latest news release and other corporate documents
             via FAX -- at no cost -- please dial 1-800-PRO-INFO.
                       Enter the Company's symbol NMTI.